No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
RVNC Revance Therapeutics
- 3.780
- -0.010-0.26%
Close Apr 19 16:00 ET
- 3.880
- +0.100+2.64%
Post 16:05 ET
393.94MMarket Cap-986P/E (TTM)
3.870High3.710Low1.65MVolume3.800Open3.790Pre Close6.23MTurnover1.97%Turnover RatioLossP/E (Static)104.22MShares37.98052wk High-2.60P/B316.16MFloat Cap3.62552wk Low--Dividend TTM83.64MShs Float42.410Historical High--Div YieldTTM4.22%Amplitude3.625Historical Low3.781Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
AbbVie Working With FDA After Reports of Fake Botox Versions
Revance To Present New DAXXIFY Data At The American Academy Of Neurology 2024 Annual Meeting
– Two presentations highlighting data on DAXXIFY for the treatment of cervical dystonia, including a new analysis from ASPEN trials assessing patient-desired retreatment intervals and one abstract exa
BlackBerry, Nurix Therapeutics, Tesla And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were lower, with the Dow Jones index falling over 200 points on Tuesday.
Take Care Before Jumping Onto Revance Therapeutics, Inc. (NASDAQ:RVNC) Even Though It's 35% Cheaper
To the annoyance of some shareholders, Revance Therapeutics, Inc. (NASDAQ:RVNC) shares are down a considerable 35% in the last month, which continues a horrid run for the company. For any long-term
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Revance Therapeutics, Inc. (NASDAQ:RVNC) today announced new hire grants totaling an aggregate of 222,452 inducement restricted stock units ("RSUs") to 29 employees. The RSUs vest over four years, with 25% of the
Survey Finds GLP-1 Users More Inclined to Get Aesthetic Procedures
Comments
Despite strong revenue growth, the significant share price drop indicates potential unresolved company challenges. It's advised to scrutinize the stock and forecasts before purchase.
Even After Rising 34% This Past Week, Revance Therapeutics (NASDAQ:RVNC) Shareholders Are Still Down 77% Over the Past Year
ColumnsRevance Therapeutics -14% on Preliminary Q4, FY24 Outlook
$Revance Therapeutics(RVNC.US$ Monday showed sales volumn rose 22% in Q3, reflecting positive feedback on the product's performance profile and the new pricing strategy. The firm predicted an unaudited Q4 and full-year 2023 revenue between $58 million and $59 million and $212 million and $213 million, representing approximately 28% and 80% YoY growth, respectively.
1
Concerns raised by insiders' stock selling. CEO Mark Foley's sale was price-wise favorable. Despite no recent insider purchase, the 1.9% insider stake suggests alignment with shareholders.
Despite predictions of Revance Therapeutics outperforming industry revenue growth, anticipated losses for next year have increased, hinting at future challenges. Significant forecast downgrades may amplify market skepticism towards the business.
Despite strong revenue growth, the company's falling stock suggests pessimism among investors. The firm's consistent losses intensify concerns. Over the long term, Revance Therapeutics' performance could reveal persistent challenges, necessitating careful evaluation prior to investment.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg